Search details
1.
Improved Outcomes with Enzalutamide in Biochemically Recurrent Prostate Cancer.
N Engl J Med
; 389(16): 1453-1465, 2023 Oct 19.
Article
in English
| MEDLINE | ID: mdl-37851874
2.
Talazoparib plus enzalutamide in men with first-line metastatic castration-resistant prostate cancer (TALAPRO-2): a randomised, placebo-controlled, phase 3 trial.
Lancet
; 402(10398): 291-303, 2023 07 22.
Article
in English
| MEDLINE | ID: mdl-37285865
3.
The transcription factor Lyl-1 regulates lymphoid specification and the maintenance of early T lineage progenitors.
Nat Immunol
; 13(8): 761-9, 2012 Jul 08.
Article
in English
| MEDLINE | ID: mdl-22772404
4.
Enzalutamide and Survival in Nonmetastatic, Castration-Resistant Prostate Cancer.
N Engl J Med
; 382(23): 2197-2206, 2020 06 04.
Article
in English
| MEDLINE | ID: mdl-32469184
5.
Avelumab alone or in combination with chemotherapy versus chemotherapy alone in platinum-resistant or platinum-refractory ovarian cancer (JAVELIN Ovarian 200): an open-label, three-arm, randomised, phase 3 study.
Lancet Oncol
; 22(7): 1034-1046, 2021 07.
Article
in English
| MEDLINE | ID: mdl-34143970
6.
Prognostic value of circulating Bcl-2/IgH levels in patients with follicular lymphoma receiving first-line immunochemotherapy.
Blood
; 126(12): 1407-14, 2015 Sep 17.
Article
in English
| MEDLINE | ID: mdl-26239087
7.
TAK-228 (formerly MLN0128), an investigational oral dual TORC1/2 inhibitor: A phase I dose escalation study in patients with relapsed or refractory multiple myeloma, non-Hodgkin lymphoma, or Waldenström's macroglobulinemia.
Am J Hematol
; 91(4): 400-5, 2016 Jun.
Article
in English
| MEDLINE | ID: mdl-26800393
8.
Ataxin1L is a regulator of HSC function highlighting the utility of cross-tissue comparisons for gene discovery.
PLoS Genet
; 9(3): e1003359, 2013 Mar.
Article
in English
| MEDLINE | ID: mdl-23555280
9.
Multiple myeloma-related deregulation of bone marrow-derived CD34(+) hematopoietic stem and progenitor cells.
Blood
; 120(13): 2620-30, 2012 Sep 27.
Article
in English
| MEDLINE | ID: mdl-22517906
10.
First-line talazoparib with enzalutamide in HRR-deficient metastatic castration-resistant prostate cancer: the phase 3 TALAPRO-2 trial.
Nat Med
; 30(1): 257-264, 2024 Jan.
Article
in English
| MEDLINE | ID: mdl-38049622
11.
Clinical Outcomes of Enzalutamide in Metastatic Hormone-sensitive Prostate Cancer in Patients Aged <75 and ≥75 Years: ARCHES Post Hoc Analysis.
Eur Urol Oncol
; 2023 Dec 09.
Article
in English
| MEDLINE | ID: mdl-38072761
12.
The Efficacy of Enzalutamide plus Androgen Deprivation Therapy in Oligometastatic Hormone-sensitive Prostate Cancer: A Post Hoc Analysis of ARCHES.
Eur Urol
; 84(2): 229-241, 2023 08.
Article
in English
| MEDLINE | ID: mdl-37179240
13.
The level of minimal residual disease in the bone marrow of patients with multiple myeloma before high-dose therapy and autologous blood stem cell transplantation is an independent predictive parameter.
Biol Blood Marrow Transplant
; 18(3): 423-431.e3, 2012 Mar.
Article
in English
| MEDLINE | ID: mdl-21745451
14.
Upfront allogeneic blood stem cell transplantation for patients with high-risk myelodysplastic syndrome or secondary acute myeloid leukemia using a FLAMSA-based high-dose sequential conditioning regimen.
Biol Blood Marrow Transplant
; 18(3): 466-72, 2012 Mar.
Article
in English
| MEDLINE | ID: mdl-21963618
15.
Therapy-related myeloid neoplasms following treatment with radioiodine.
Haematologica
; 97(2): 206-12, 2012 Feb.
Article
in English
| MEDLINE | ID: mdl-21993688
16.
Improved Survival With Enzalutamide in Patients With Metastatic Hormone-Sensitive Prostate Cancer.
J Clin Oncol
; 40(15): 1616-1622, 2022 05 20.
Article
in English
| MEDLINE | ID: mdl-35420921
17.
CD34+ progenitor cells mobilized by natalizumab are not a relevant reservoir for JC virus.
Mult Scler
; 17(2): 151-6, 2011 Feb.
Article
in English
| MEDLINE | ID: mdl-21078695
18.
Publisher Correction: First-line talazoparib with enzalutamide in HRR-deficient metastatic castration-resistant prostate cancer: the phase 3 TALAPRO-2 trial.
Nat Med
; 30(5): 1505, 2024 May.
Article
in English
| MEDLINE | ID: mdl-38297094
19.
Unrelated umbilical cord blood transplantation as salvage treatment for engraftment failure following autologous stem cell transplantation.
Leuk Res
; 32(7): 1157-9, 2008 Jul.
Article
in English
| MEDLINE | ID: mdl-18221996
20.
Phase I study of the investigational oral mTORC1/2 inhibitor sapanisertib (TAK-228): tolerability and food effects of a milled formulation in patients with advanced solid tumours.
ESMO Open
; 3(2): e000291, 2018.
Article
in English
| MEDLINE | ID: mdl-29464110